

Santiago Perez-Lloret

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1949874/santiago-perez-lloret-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

123
papers

3,695
citations

31
h-index

57
g-index

140
ext. papers

4,402
ext. citations

4.2
avg. IF

5.46
L-index

#	Paper	IF	Citations
123	On the diagnosis of pain in Parkinson disease: a mechanism-based approach.. <i>Pain</i> , 2022 , 163, e495	8	
122	Risk of Myocarditis and Pericarditis among Young Adults following mRNA COVID-19 Vaccinations. <i>Vaccines</i> , 2022 , 10, 722	5.3	1
121	How much time is needed in clinical practice to reach a diagnosis of clinically established Parkinson's disease?. <i>Parkinsonism and Related Disorders</i> , 2021 , 92, 53-58	3.6	2
120	Value and Methods of Pharmacovigilance in the Monitoring of Drug Safety in Parkinson's Disease. <i>Neuromethods</i> , 2021 , 177-190	0.4	
119	The Parkinson disease pain classification system: results from an international mechanism-based classification approach. <i>Pain</i> , 2021 , 162, 1201-1210	8	11
118	Melatonin as a Chronobiotic and Cytoprotective Agent in Parkinson's Disease. <i>Frontiers in Pharmacology</i> , 2021 , 12, 650597	5.6	12
117	Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy: The MSA-FLUO Trial. <i>Movement Disorders</i> , 2021 , 36, 1704-1711	7	3
116	The Renin-Angiotensin System Modulates Dopaminergic Neurotransmission: A New Player on the Scene. <i>Frontiers in Synaptic Neuroscience</i> , 2021 , 13, 638519	3.5	2
115	RBD-specific polyclonal F(ab) fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial. <i>EClinicalMedicine</i> , 2021 , 34, 100843	11.3	23
114	Effects of angiotensin type 1 receptor antagonists on Parkinson's disease progression: An exploratory study in the PPMI database. <i>Parkinsonism and Related Disorders</i> , 2021 , 86, 34-37	3.6	1
113	Cross-sectional analysis of the Parkinson's disease Non-motor International Longitudinal Study baseline non-motor characteristics, geographical distribution and impact on quality of life. <i>Scientific Reports</i> , 2021 , 11, 9611	4.9	6
112	Diagnosis and Management of Pain in Parkinson's Disease: A New Approach. <i>Drugs and Aging</i> , 2021 , 38, 559-577	4.7	2
111	Assessment of Ataxia Rating Scales and Cerebellar Functional Tests: Critique and Recommendations. <i>Movement Disorders</i> , 2021 , 36, 283-297	7	16
110	Drooling and dysphagia in Parkinson's disease. <i>International Review of Movement Disorders</i> , 2021 , 147-178		
109	Self-directed video versus instructor-based neonatal resuscitation training: a randomized controlled blinded non-inferiority multicenter international study. <i>Journal of Perinatology</i> , 2021 , 41, 1583 ¹ -1589 ⁰		
108	Sleep disruption in medicine students and its relationship with impaired academic performance: A systematic review and meta-analysis. <i>Sleep Medicine Reviews</i> , 2020 , 53, 101333	10.2	11
107	Role of Astrocytic Dysfunction in the Pathogenesis of Parkinson's Disease Animal Models from a Molecular Signaling Perspective. <i>Neural Plasticity</i> , 2020 , 2020, 1859431	3.3	12

106	State-of-the-art pharmacotherapy for autonomic dysfunction in Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2020 , 21, 445-457	4	5
105	Utilization Patterns of Amantadine in Parkinson's Disease Patients Enrolled in the French COPARK Study. <i>Drugs and Aging</i> , 2020 , 37, 215-223	4.7	7
104	Prevalence and factors related to orthostatic syndromes in recently diagnosed, drug-naïve patients with Parkinson disease. <i>Clinical Autonomic Research</i> , 2020 , 30, 265-271	4.3	8
103	Parkinson's Disease in the Era of a Novel Respiratory Virus Pandemic. <i>Frontiers in Neurology</i> , 2020 , 11, 995	4.1	4
102	Excessive buccal saliva in patients with Parkinson's disease of the French COPARK cohort. <i>Journal of Neural Transmission</i> , 2020 , 127, 1607-1617	4.3	1
101	Therapeutic strategies for Parkinson's disease: promising agents in early clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 1249-1267	5.9	6
100	Test-retest reliability of the Friedreich's ataxia rating scale. <i>Annals of Clinical and Translational Neurology</i> , 2020 , 7, 1708-1712	5.3	6
99	A Pilot Cross-Sectional Study to Investigate the Biomarker Potential of Phosphorylated Neurofilament-H and Immune Mediators of Disability in Patients With 5 Year Relapsing-Remitting Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2019 , 10, 1046	4.1	3
98	Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 635-645	4	6
97	Genetic Factors Influencing the Development and Treatment of Cognitive Impairment and Psychosis in Parkinson's Disease 2019 , 359-370		
96	Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review. <i>Movement Disorders</i> , 2019 , 34, 180-198	7	357
95	Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia. <i>Journal of Neural Transmission</i> , 2018 , 125, 1237-1250	4.3	41
94	Movement Disorders After Exposure to Antipsychotic Drugs in Patients With Depressive Disorders. <i>Clinical Neuropharmacology</i> , 2018 , 41, 177-180	1.4	0
93	Predictors of Cardiovascular Autonomic Neuropathy Onset and Progression in a Cohort of Type 1 Diabetic Patients. <i>Journal of Diabetes Research</i> , 2018 , 2018, 5601351	3.9	4
92	Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson's disease. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 1163-1173	5.9	24
91	L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life: the COPARK survey. <i>European Journal of Neurology</i> , 2017 , 24, 1532-1538	6	33
90	A Randomized, Open-Label, Two-Way Crossover, Single-Dose Bioequivalence Study of Temozolomide 200 mg/m (Dralitem vs. Temodal Capsules) in Patients with Primary Tumors of the Central Nervous System Under Fasting Conditions. <i>Drugs in R and D</i> , 2017 , 17, 427-434	3.4	5
89	A multifactorial study on nutritional status, binge eating and physical activity as main factors directly influencing body weight in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2017 , 3, 17	9.7	5

88	Neuropsychiatric Symptoms Related to Cholinergic Deficits in Parkinson's Disease 2017 , 375-388		
87	Clinical Effects of a 6-Month Treatment Course of Ibandronate, Vitamin D, and Calcium in Postmenopausal Women from Central America: Results of a Multinational, Prospective Pilot Study. <i>Integrative Medicine International</i> , 2016 , 3, 82-88	1.4	
86	Alteration of Biological Rhythms in Diseases of the Central Dopaminergic System: Focus on Parkinson's Disease 2016 , 91-114		
85	Pharmacotherapies for Parkinson's disease symptoms related to cholinergic degeneration. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 2405-2415	4	15
84	Factors Related to Early Clinical Effects of Quetiapine Extended-Release: A Multinational, Prospective, Observational Study. <i>Clinical Drug Investigation</i> , 2016 , 36, 491-7	3.2	1
83	Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease. <i>CNS Drugs</i> , 2016 , 30, 703-17	6.7	28
82	New insights into orthostatic hypotension in multiple system atrophy: a European multicentre cohort study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 554-61	5.5	30
81	The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2016 , 16, 245-58	4.3	16
80	Comparison of Olfactory Identification Patterns among Parkinson's Disease Patients from Different Countries. <i>Chemical Senses</i> , 2016 , 41, 77-83	4.8	9
79	Associations between Anticholinergic Burden and Adverse Health Outcomes in Parkinson Disease. <i>PLoS ONE</i> , 2016 , 11, e0150621	3.7	68
78	Associations Between Cardiovascular Events and Nonergot Dopamine Agonists in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 257-267	2.2	6
77	Deficits in cholinergic neurotransmission and their clinical correlates in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2016 , 2, 16001	9.7	93
76	Rating Scales for Pain in Parkinson's Disease: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 527-537	2.2	27
75	Sensory abnormalities and pain in Parkinson disease and its modulation by treatment of motor symptoms. <i>European Journal of Pain</i> , 2016 , 20, 151-65	3.7	58
74	Current Concepts in the Treatment of Multiple System Atrophy. <i>Movement Disorders Clinical Practice</i> , 2015 , 2, 6-16	2.2	15
73	Trends in inpatient antiparkinson drug use in the USA, 2001-2012. <i>European Journal of Clinical Pharmacology</i> , 2015 , 71, 1011-9	2.8	31
72	Falls in ambulatory non-demented patients with Parkinson's disease. <i>Journal of Neural Transmission</i> , 2015 , 122, 1447-55	4.3	41
71	Subjective sleep dysfunction and insomnia symptoms in Parkinson's disease: Insights from a cross-sectional evaluation of the French CoPark cohort. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 1323-9	3.6	35

70	New treatments for levodopa-induced motor complications. <i>Movement Disorders</i> , 2015 , 30, 1451-60	7	82
69	Olfactory Dysfunction Evaluation Is Not Affected by Comorbid Depression in Parkinson's Disease. <i>Movement Disorders</i> , 2015 , 30, 1275-9	7	14
68	Assessment of Arterial Stiffness by 24-Hour Ambulatory Blood Pressure Monitoring in Nocturnal Hypertensive or Normotensive Subjects. <i>Integrative Medicine International</i> , 2015 , 1, 130-135	1.4	
67	Management of constipation in Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 547-57		32
66	Design and development of a novel supportive care product for the treatment of sialorrhea in Parkinson's disease. <i>Current Topics in Medicinal Chemistry</i> , 2015 , 15, 939-54	3	2
65	Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 1097-107	4	20
64	A cross-sectional study on drug use in multiple system atrophy. <i>CNS Drugs</i> , 2014 , 28, 483-90	6.7	8
63	Autosomal dominant cerebellar ataxias: a systematic review of clinical features. <i>European Journal of Neurology</i> , 2014 , 21, 607-15	6	90
62	Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients. <i>Expert Opinion on Drug Safety</i> , 2014 , 13, 351-60	4.1	31
61	Droxidopa for the treatment of neurogenic orthostatic hypotension and other symptoms of neurodegenerative disorders. <i>Expert Opinion on Orphan Drugs</i> , 2014 , 2, 509-522	1.1	3
60	Movement Disorders in Autosomal Dominant Cerebellar Ataxias: A Systematic Review. <i>Movement Disorders Clinical Practice</i> , 2014 , 1, 154-160	2.2	28
59	Rotigotine Transdermal Patch for the Treatment of Restless Legs Syndrome. <i>Integrative Medicine International</i> , 2014 , 1, 32-43	1.4	
58	Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease. <i>JAMA Neurology</i> , 2014 , 71, 884-90	17.2	159
57	Effects of different "relaxing" music styles on the autonomic nervous system. <i>Noise and Health</i> , 2014 , 16, 279-84	0.9	19
56	Drug-Induced Movement Disorders in Elderly Patients 2014 , 87-115		
55	Orthostatic hypotension in Parkinson's disease. <i>Neurodegenerative Disease Management</i> , 2013 , 3, 363-377.8		1
54	Adverse drug reactions with Selegiline and Rasagiline compared to Levodopa and Ropinirole: A study in the French Pharmacovigilance Database. <i>Journal of the Neurological Sciences</i> , 2013 , 333, e129	3.2	3
53	Emerging drugs for autonomic dysfunction in Parkinson's disease. <i>Expert Opinion on Emerging Drugs</i> , 2013 , 18, 39-53	3.7	22

52	A multi-step pathway connecting short sleep duration to daytime somnolence, reduced attention, and poor academic performance: an exploratory cross-sectional study in teenagers. <i>Journal of Clinical Sleep Medicine</i> , 2013 , 9, 469-73	3.1	53
51	Rotigotine transdermal patch for the treatment of Parkinson's Disease. <i>Fundamental and Clinical Pharmacology</i> , 2013 , 27, 81-95	3.1	17
50	Validation of a new scale to assess olfactory dysfunction in patients with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012 , 18, 358-61	3.6	35
49	Factors related to orthostatic hypotension in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2012 , 18, 501-5	3.6	42
48	A proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson's disease. <i>Fundamental and Clinical Pharmacology</i> , 2012 , 26, 557-64	3.1	18
47	Cardiac autonomic activity predicts dominance in verbal over spatial reasoning tasks: results from a preliminary study. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2012 , 167, 78-80	2.4	2
46	Emerging analgesic drugs for Parkinson's disease. <i>Expert Opinion on Emerging Drugs</i> , 2012 , 17, 157-71	3.7	27
45	Do Parkinson's disease patients disclose their adverse events spontaneously?. <i>European Journal of Clinical Pharmacology</i> , 2012 , 68, 857-65	2.8	16
44	Oro-buccal symptoms (dysphagia, dysarthria, and sialorrhea) in patients with Parkinson's disease: preliminary analysis from the French COPARK cohort. <i>European Journal of Neurology</i> , 2012 , 19, 28-37	6	57
43	Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. <i>Clinical Neuropharmacology</i> , 2012 , 35, 261-5	1.4	64
42	Pregabalin beneficial effects on sleep quality or health-related quality of life are poorly correlated with reduction on pain intensity after an 8-week treatment course. <i>Clinical Neuropharmacology</i> , 2012 , 35, 21-4	1.4	9
41	Drugs associated with restless legs syndrome: a case/noncase study in the French Pharmacovigilance Database. <i>Journal of Clinical Psychopharmacology</i> , 2012 , 32, 824-7	1.7	22
40	Bioequivalence of lamotrigine 50-mg tablets in healthy male volunteers: a randomized, single-dose, 2-period, 2-sequence crossover study. <i>Arzneimittelforschung</i> , 2012 , 62, 470-6		1
39	A double-blind, placebo-controlled, randomized, crossover pilot study of the safety and efficacy of multiple doses of intra-oral tropicamide films for the short-term relief of sialorrhea symptoms in Parkinson's disease patients. <i>Journal of the Neurological Sciences</i> , 2011 , 310, 248-50	3.2	29
38	Nonmotor symptoms groups in Parkinson's disease patients: results of a pilot, exploratory study. <i>Parkinson's Disease</i> , 2011 , 2011, 473579	2.6	8
37	Sleep habits, alertness, cortisol levels, and cardiac autonomic activity in short-distance bus drivers: differences between morning and afternoon shifts. <i>Journal of Occupational and Environmental Medicine</i> , 2011 , 53, 806-11	2	21
36	Pramipexole for the treatment of early Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2011 , 11, 925-35	4.3	16
35	Drug-induced parkinsonism: a review of 17 years' experience in a regional pharmacovigilance center in France. <i>Movement Disorders</i> , 2011 , 26, 2226-31	7	99

34	The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26 Suppl 3, S42-80	7	599
33	Safety of rasagiline for the treatment of Parkinson's disease. <i>Expert Opinion on Drug Safety</i> , 2011 , 10, 633-43	4.1	21
32	Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 2221-30	4	7
31	Actigraphic evaluation of motor fluctuations in patients with Parkinson's disease. <i>International Journal of Neuroscience</i> , 2010 , 120, 137-43	2	12
30	Activity-rest rhythm abnormalities in Parkinson's disease patients are related to dopaminergic therapy. <i>International Journal of Neuroscience</i> , 2010 , 120, 11-6	2	15
29	Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease. <i>CNS Drugs</i> , 2010 , 24, 941-68	6.7	79
28	Adverse drug reactions to dopamine agonists: a comparative study in the French Pharmacovigilance Database. <i>Movement Disorders</i> , 2010 , 25, 1876-80	7	19
27	Gender differences in age-related increase of asleep blood pressure. <i>Archives of Gerontology and Geriatrics</i> , 2010 , 50, 319-22	4	5
26	Heart rate nonlinear dynamics during sudden hypoxia at 8230 m simulated altitude. <i>Wilderness and Environmental Medicine</i> , 2010 , 21, 4-10	1.4	27
25	Decision-making in Parkinson's disease patients with and without pathological gambling. <i>European Journal of Neurology</i> , 2010 , 17, 97-102	6	88
24	Does clinical intolerance to a diagnostic acute levodopa challenge differentiate multiple system atrophy from PD?. <i>International Journal of Neuroscience</i> , 2009 , 119, 2257-61	2	4
23	Parkinson's disease sleep scale, sleep logs, and actigraphy in the evaluation of sleep in parkinsonian patients. <i>Journal of Neurology</i> , 2009 , 256, 1480-4	5.5	30
22	Irritability, psychomotor agitation and progressive insomnia induced by bilateral stimulation of the area surrounding the dorsal subthalamic nucleus (zona incerta) in Parkinson's disease patients. <i>Journal of Neurology</i> , 2009 , 256, 2091-3	5.5	9
21	Addenbrooke's Cognitive Examination validation in Parkinson's disease. <i>European Journal of Neurology</i> , 2009 , 16, 142-7	6	63
20	Brief review: diurnal rhythms, obesity and educational achievement in South american cultures. <i>International Journal of Neuroscience</i> , 2009 , 119, 1091-104	2	3
19	Rotigotine transdermal delivery for the treatment of Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 677-91	4	37
18	Pregabalin-induced parkinsonism: a case report. <i>Clinical Neuropharmacology</i> , 2009 , 32, 353-4	1.4	15
17	Nocturnal hypertension defined by fixed cut-off limits is a better predictor of left ventricular hypertrophy than non-dipping. <i>International Journal of Cardiology</i> , 2008 , 127, 387-9	3.2	31

16	Validation of the sleep related items of the Non-motor Symptoms Questionnaire for Parkinson's disease (NMSQuest). <i>Parkinsonism and Related Disorders</i> , 2008 , 14, 641-5	3.6	12
15	Blunting of circadian rhythms and increased acrophase variability in sleep-time hypertensive subjects. <i>Chronobiology International</i> , 2008 , 25, 99-113	3.6	11
14	Validation of a new scale for the evaluation of sialorrhea in patients with Parkinson's disease. <i>Movement Disorders</i> , 2007 , 22, 107-11	7	59
13	Sleep disordered breathing and daytime sleepiness are associated with poor academic performance in teenagers. A study using the Pediatric Daytime Sleepiness Scale (PDSS). <i>Sleep</i> , 2007 , 30, 1698-703	1.1	114
12	Dyskinesias induced by subthalamotomy in Parkinson's disease are unresponsive to amantadine. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006 , 77, 172-4	5.5	19
11	Infradian awake and asleep systolic and diastolic blood pressure rhythms in humans. <i>Journal of Hypertension</i> , 2006 , 24, 1273-9	1.9	8
10	Gender-related differences in urinary 6-sulfatoxymelatonin levels in obese pubertal individuals. <i>Journal of Pineal Research</i> , 2006 , 40, 214-8	10.4	29
9	Melatonin treatment counteracts the hyperthermic effect of lipopolysaccharide injection in the Syrian hamster. <i>Neuroscience Letters</i> , 2005 , 389, 169-72	3.3	11
8	Disruption of ultradian and circadian rhythms of blood pressure in nondipper hypertensive patients. <i>Hypertension</i> , 2004 , 44, 311-5	8.5	15
7	Low urinary 6-sulfatoxymelatonin levels in patients with severe congestive heart failure. <i>Endocrine</i> , 2003 , 22, 245-8		32
6	Attitudes towards treatment among patients suffering from sleep disorders. A Latin American survey. <i>BMC Family Practice</i> , 2003 , 4, 17	2.6	13
5	Cerebroventricular administration of interferon-gamma modifies locomotor activity in the golden hamster. <i>NeuroSignals</i> , 2003 , 12, 89-94	1.9	21
4	A multifactorial approach employing melatonin to accelerate resynchronization of sleep-wake cycle after a 12 time-zone westerly transmeridian flight in elite soccer athletes. <i>Journal of Pineal Research</i> , 2002 , 32, 41-6	10.4	54
3	Effect of melatonin on changes in locomotor activity rhythm of Syrian hamsters injected with beta amyloid peptide 25-35 in the suprachiasmatic nuclei. <i>Cellular and Molecular Neurobiology</i> , 2002 , 22, 699-709	4.6	27
2	A double blind-placebo controlled study on melatonin efficacy to reduce anxiolytic benzodiazepine use in the elderly. <i>Neuroendocrinology Letters</i> , 2002 , 23, 55-60	0.3	42
1	Melatonin in sleep disorders and jet-lag. <i>Neuroendocrinology Letters</i> , 2002 , 23 Suppl 1, 9-13	0.3	11